Information Provided By: 
Fly News Breaks for October 19, 2015
BLUE
Oct 19, 2015 | 16:12 EDT
Oppenheimer analyst Wendy Lam started shares of bluebird bio with an Outperform rating and $162 price target. The company is "poised to revolutionize" the treatment of two blood disorders, beta thalassemia major and sickle cell disease, Lam tells investors in a research note. The shares are attractively priced at current levels, she argues.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
